瑞银发表研究报告指，微创机械人-B(2252.HK)为中国领先的手术机械人公司，在中国、美国和欧盟拥有三款商业化产品，产品线覆盖全面，销售及研发团队经验丰富，与内地同业相比具优势，预料在当局的国产替代政策下，微创机械人可挑战跨国企业在中国市场的主导地位。
该行指，MedBot第二代透脉机械人获批及新产品发布将成为公司今年主要催化剂，预测2022至2024年收入复合年增长率达907%，首次给予微创机械人-B“买入”评级，目标价43港元。现股价相信于今年市销增长率(PSG)0.23倍，而市场上缺乏国产手术机械人同行比较，虽然较创新医疗技术H股(0.17倍)有溢价，但与全球同业(0.88倍)比较存在折让，认为市场并未充分体现其领先地位和强劲的增长潜力。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.